Sunhawk Vision Biotech, Inc. (TPEX:7759)

Market Cap	2.00B -59.7%
Revenue (ttm)	n/a
Net Income	-172.39M
EPS	-2.47
Shares Out	70.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,765
Open	28.00
Previous Close	28.45
Day's Range	27.70 - 30.00
52-Week Range	25.60 - 83.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About Sunhawk Vision Biotech

Sunhawk Vision Biotech, Inc., a drug development company, engages in the research and development of children's myopia eye drops, dry eye drops, and other nucleic acid new drugs for the treatment of ocular surface diseases in Taiwan. The company develops SHJ002 eye drops, which have completed a Phase 2 clinical trial for the treatment of dry eye disease in adult patients and corneal erosion in patients with Sjogren’s syndrome, as well as in a Phase 2 clinical trial for myopia control in young children. Sunhawk Vision Biotech, Inc. was founded i...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7759

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 4, 2026

Data Sources Report a data error